These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 39011505)

  • 21. Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.
    Go M; Noguchi Y; Masuda R; Asano H; Kimura M; Usami E; Yoshimura T
    Int J Cancer; 2024 Sep; 155(5):849-853. PubMed ID: 38619193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
    Kappel C; Elliott MJ; Kumar V; Nadler MB; Desnoyers A; Amir E
    Sci Rep; 2024 Feb; 14(1):3129. PubMed ID: 38326452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.
    Takeda T; Sugimoto S; Matsumoto J; Iwata N; Nakamoto A; Ozaki AF; Hamano H; Ariyoshi N; Zamami Y
    Int J Clin Pharm; 2024 Apr; 46(2):536-541. PubMed ID: 38240964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
    Ren X; Yan C; Tian L; Cui X
    Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
    Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
    EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system.
    Cheng Q; Shi X; Zhao Y; Zou S; Sun M
    Expert Opin Drug Saf; 2024 May; 23(5):637-648. PubMed ID: 38564277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
    Shu Y; Wang L; Ding Y; Zhang Q
    Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
    Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
    BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.
    Nawa H; Niimura T; Yagi K; Goda M; Zamami Y; Ishizawa K
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1402. PubMed ID: 33939324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
    D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D
    Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
    Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
    Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
    Iuliani M; Simonetti S; Ribelli G; Napolitano A; Longo UG; Vincenzi B; Orsaria P; Denaro V; Tonini G; Santini D; Francesco P
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India.
    Das Majumdar SK; Barik SK; Pattanaik A; Das DK; Parida DK
    Cureus; 2024 Jan; 16(1):e52172. PubMed ID: 38344632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line CDK4/6 inhibitor-based combinations for HR+/HER2- advanced breast cancer: A Bayesian network meta-analysis.
    Guo X; Zhou Y; Zhang K; Lu W; Zhong X; Wu S; Shen L; Chen H; Chen Y
    J Evid Based Med; 2024 Mar; 17(1):106-118. PubMed ID: 38102891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.